TPD | Jotup

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Retrieved on:

星期三, 七月 5, 2023

CCCC, Clinical trial, Mutation, TPD, NSCLC, Lung cancer, Science, Patient, EGFR, National Medical Products Administration, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry

This milestone marks C4T’s fourth IND clearance from its proprietary TORPEDO® platform.

Key Points:

This milestone marks C4T’s fourth IND clearance from its proprietary TORPEDO® platform.
In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation.
The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China.
C4T expects to initiate clinical trial activities outside Greater China following the completion of Betta Pharmaceuticals’ Phase 1 dose escalation study in Greater China.

KIWI Launches Ceramic Coil Disposable Vape KIWI GO with FEELM Max Technology

Retrieved on:

星期三, 六月 28, 2023

Retail, Tobacco, Consumer Electronics, Technology, Specialty, Herbal cigarette, TPD, Industrial design, Transformer, KIWI

KIWI, an Italian industry leader in vaping technology, proudly announces the launch of KIWI GO in Italy, featuring FEELM Max, the world’s first ceramic coil disposable solution.

Key Points:

KIWI, an Italian industry leader in vaping technology, proudly announces the launch of KIWI GO in Italy, featuring FEELM Max, the world’s first ceramic coil disposable solution.
KIWI GO, featuring FEELM Max in 2022, the world's first ceramic coil disposable solution, represents a groundbreaking advancement in vaping technology.
Collaborating with FEELM, the world's leading vaping technology provider and flagship brand of atomization tech company SMOORE, KIWI has harnessed the power of FEELM Max to create KIWI GO.
Mattia Sparacino, CEO and founder of KIWI Vapor, highlighted the pivotal role played by the ceramic coil technology in KIWI GO.

Global e-Cigarettes Market Database 2023: Analysis of Key Vaping Markets in 50+ Countries - ResearchAndMarkets.com

Retrieved on:

星期二, 六月 27, 2023

Technology, Consumer Electronics, Database, 60ml: Last Order, TPD, Nicotine, Online shopping

The "Global Market Database: E-cigarettes" database has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Market Database: E-cigarettes" database has been added to ResearchAndMarkets.com's offering.
This database provides a detailed analysis of key vaping markets in more than 50 countries in seven regions of the world.
The filtering tool enables you to view dashboards of each country and make quick comparisons of country-specific data.
The retail channel analysis offers a split between online retailers, physical vape stores, and other brick and mortar.

At the double: leading vape technology brand FEELM shows off two latest advancements in Dubai

Retrieved on:

星期三, 六月 21, 2023

Tobacco, Retail, Specialty, Other Retail, Taste, Smoker, IPO, TPD, Multimedia, Research, UK Vaping Industry Association, Attention, Sensation, Assistant, Intel Core, HEXA, Herbal cigarette, Electric battery, Toy

The pioneering advancements both earned attention from the industry and are already appearing in devices from globally recognised brands.

Key Points:

The pioneering advancements both earned attention from the industry and are already appearing in devices from globally recognised brands.
FEELM, as a responsible brand always compliant with laws and regulations, rolls out a groundbreaking technology with which 2 ml disposables showcase higher product performance.
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider.
Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.

SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

Retrieved on:

星期二, 六月 20, 2023

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary and global research company focused on harnessing and engineering “molecular glues,” a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 50 years’ experience in finance, strategy, and risk governance to the SEED Therapeutics Board.

Key Points:

He brings almost 50 years’ experience in finance, strategy, and risk governance to the SEED Therapeutics Board.
He continues to serve as Board Member for Hong Kong Exchange listed Wuxi Biologics (where he is Chairman of the Audit Committee).
“It is a privilege to join the SEED Therapeutics Board and to work alongside our Co-Founding scientists and visionaries who are recognized pioneers in the field of Targeted Protein Degradation,” said Mr. Tai.
It’s truly exciting to see Management, the Board, and Co-Founders to be so obsessed with SEED Therapeutics’ opportunity to be First to Market and Best in Class.”

Plug Teams Up with Avina to Decarbonize Commercial Trucking

Retrieved on:

星期三, 六月 14, 2023

Hydrogen, Partnership, CSO, TPD, National Clean Energy Business Plan Competition, Carbon, PEM, Renewable energy, Fundación Avina

Plug’s electrolyzers will support the first hydrogen production facility for heavy-duty trucks in Southern California.

Key Points:

Plug’s electrolyzers will support the first hydrogen production facility for heavy-duty trucks in Southern California.
Plug has a right of first refusal to supply electrolyzers for Avina’s next hydrogen production facility.
Each of Plug’s electrolyzer units will enable Avina to produce up to two metric tons per day (TPD) of green hydrogen, or 730 metric tons annually.
Delivery of the systems is expected in Q2 2024, and the production facility is anticipated to be fully operational in mid-2024.

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Retrieved on:

星期三, 六月 14, 2023

WATERTOWN, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.

Key Points:

The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.
“We are proud and excited to be the first company to have shown clinical translation of our degraders’ profiles across three programs and across multiple diseases and indications.
Data reported from the 3 completed dose levels (DL1-3) found:
Plasma exposure increased with dose, reaching levels close to those predicted to be efficacious.
KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose.

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Retrieved on:

星期五, 六月 9, 2023

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. On June 14, a KT-333 poster will be released at ICML and presented on June 16. Kymera will share updated results from both programs in conjunction with the poster release on June 14.

Key Points:

Kymera will share updated results from both programs in conjunction with the poster release on June 14.
KT-333 is designed as a potent degrader of STAT3, a transcriptional regulator that has been linked to numerous cancers as well as to inflammatory and autoimmune diseases.
As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.
As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

Retrieved on:

星期五, 六月 9, 2023

The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.

Key Points:

The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.
KT-253 targets MDM2, the crucial regulator of the most common tumor suppressor, p53.
p53 remains intact (wild type) in close to 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
Patients in the KT-253 Phase 1 dose escalation study will receive IV doses of KT-253 administered once every 3 weeks.

Plug Power Makes Major Strategic Move into Finland’s Green Hydrogen Economy with its Proven PEM Electrolyzer and Liquefaction Technology

Retrieved on:

星期二, 五月 30, 2023

Kokkola, Finland: This site is expected to generate 85TPD of liquid green hydrogen, and up to 700 kt of green ammonia per year, using 1GW of electrolyzers.

Key Points:

Kokkola, Finland: This site is expected to generate 85TPD of liquid green hydrogen, and up to 700 kt of green ammonia per year, using 1GW of electrolyzers.
The liquid green hydrogen will be produced for local use and for export to western Europe from the Port of Kokkola.
“In Kristinestad, we have been working for a long time on developing green energy through wind power, solar power, and hydrogen.
Plug’s planned green hydrogen production sites are expected to create around 1,000 direct jobs and over 3,000 indirect jobs, significantly boosting the local economy.